Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

Oncotarget

Volumn 6, Issue 31, 2015, Pages 31604-31612

  Vincenzi, Bruno ^a   Cremolini, Chiara ^b   Sartore Bianchi, Andrea ^c   Russo, Antonio ^d   Mannavola, Francesco ^e   Perrone, Giuseppe ^a   Pantano, Francesco ^a   Loupakis, Fotios ^b   Rossini, Daniele ^b   Ongaro, Elena ^f   Bonazzina, Erica ^c   Dell'Aquila, Emanuela ^a   Imperatori, Marco ^a   Zoccoli, Alice ^a   Bronte, Giuseppe ^d   Maglio, Giovanna De ^f   Fontanini, Gabriella ^g   Natoli, Clara ^h   Falcone, Alfredo ^b   Santini, Daniele ^a   Onetti Muda, Andrea ^a   Siena, Salvatore ^c   Tonini, Giuseppe ^a   Aprile, Giuseppe ^f   more..

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY HOSPITAL OF UDINE   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h UNIVERSITY OF CHIETI   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; K Ras; Mutation rate; Prognosis

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATION RATE; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; CANCER STAGING; COLORECTAL NEOPLASMS; FOLLOW UP; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84945549001     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5231     Document Type: Article

References (28)

1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3:459-465.
2. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001; 93: 1062-1074.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-1634.
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-1417.
6. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR COSMIC 2005. Br J Cancer. 2006; 94: 318-322.
7. Ciardiello F, Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov. 2011; 1: 472-4.
8. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P et al. PanitumumabFOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369: 1023-1034.
9. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
10. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14: 749-759.
11. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
12. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26: 374-379.
13. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R et al. N Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001; 85: 692-696.
14. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27: 5931-5937.
15. Loupakis F, Cremolini C, Lonardi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Valsuani C, Silvana C, Boni C, Marcucci L, Negri F, Barone C et al. A Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol. 2014; 32: 5s, (suppl; abstr 3519).
16. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009; 101: 715-721.
17. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015; 26: 13-21.
18. Ren J, Li G, Ge J, Li X, Zhao Y Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2012; 55: 913-923.
19. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Ciardiello F, Lenz H-J, Kohne C-H, Heinemann V, Tejpar S et al. Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial. J Clin Oncol. 2014. 32: suppl 3; abstr LBA443.
20. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011; 10: 1093-1101.
21. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.
22. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum. 2011; 54: 1026-1035.
23. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L et al. A High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008; 13: 1270-1275.
24. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, Punt CJ, Nagtegaal ID KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011; 104: 1020-1026.
25. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014; 15: 454.
26. Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, Tonini G Should oncologists be aware in their clinical practice of KRAS molecular analysis? J Clin Oncol. 2011; 29: e206-7; author reply e208-209.
27. Özer-Stillman I, Strand L, Chang J, Mohamed AF, Tranbarger-Freier KE Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor. Clin Cancer Res. 2015; 21: 295-302.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCIEORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93: 387-91.